Figure 3.Box and whisker plots of selected immune marker genes for comparison of expression levels (tpm and fpkm) for MYC amplified (shaded) and non-amplified WCDT-MCRPC cases(A) tpm: CD19, p-value = 0.004; CD22, p-value <0.001; CD33, p-value = 0.004; CD68, p-value = 0.006; CD79B, p-value=0.007; MS4A1, p-value = 0.002; SPHK1, p-value = 0.037. (B) tpm: CD4, p-value = 0.038; CD79A, p-value = 0.005; CIITA, p-value = 0.017; CTSC, p-value = 0.018; ITGAX, p-value = 0.010. (C) fpkm: CD19, p-value = 0.002; CD22, p-value <0.001; CD33, p-value = 0.002; CD68, p-value = 0.004; CD79B, p-value = 0.004; MS4A1, p-value = 0.002; SPHK1, p-value = 0.021. (D) fpkm: CD4, p-value = 0.017; CD79A, p-value = 0.007; CIITA, p-value = 0.023; CTSC, p-value = 0.012; ITGAX, p-value = 0.013. For the full range of RNA-seq data corresponding to the specified immune marker genes, along with data for other immune marker genes refer to Supplementary Table 7.
